In this phase 3, double-blind, randomized study in a Chinese cohort, a clinically meaningful improvement in PFS with capivasertib–fulvestrant compared with placebo–fulvestrant was seen in patients with HR-positive/HER2-negative advanced breast cancer whose disease had progressed during or after previous treatment with an aromatase inhibitor. Here, ERBB2 is linked to breast carcinoma.